Novel Biologic Product Treats Orthopedic Lesions

The cryopreserved allograft was developed using a proprietary technique that morselizes the amnion in an effort to preserve its structural properties in an injectable form. The microscaffold created by the morselized tissue matrix includes the proteins, carbohydrates, lipids, hyaluronic acid, growth factors, and other chemical compounds naturally present in amniotic fluid and tissue.

The tissue matrix thus provides an in vivo wound covering derived from those components essential for fetal growth and development, and as a liquid wound covering, it can be injected or applied directly to the surgical site to cover or fill soft tissue defects. It can be applied directly to the surgical site, or mixed with the patient’s own blood to provide an easy to use wound covering. BioDGenesis Micronized Tissue Matrix is a product of BioDlogics (BioD; Cordova, TN, USA), which also provides other placental tissue-based products, including BioDfactor, BioDfence, BioDDryflex, and AmnioExcel.

“We believe the versatility and regenerative potential of our placental-derived products is an ideal solution for the treatment of many sports medicine injuries,” said Greg Brophy, president and CEO of BioD. “With over twenty-five patents or provisional patents filed in connection with our proprietary processing techniques and the clinical use of our products, we are committed to developing a complete line of novel tissue-based products that will enhance the quality of patient care in a broad range of clinical applications.”

Amniotic tissue is an abundant source of collagen, which provides a structural tissue matrix that facilitates, among other things, cell migration and proliferation in vivo. Interstitial collagens (types I and II) form parallel bundles that provide the mechanical integrity of the membrane, while collagens type V and VI form filamentous connections between interstitial collagens and the epithelial basement membrane.

BioDlogics



Related Links: